Pyxis Oncology Inc (NASDAQ:PYXS) shares gained 5.91% to $4.12 in overnight trading Tuesday, following the company’s leadership announcement and an upcoming clinical data webcast.
New CEO Brings Track Record Of Major Deals
The Boston-based clinical-stage biopharmaceutical company appointed Thomas Civik, interim CEO since February, as permanent CEO and Chairman, effective Sept. 4. Civik previously led Five Prime Therapeutics through its $1.9 billion acquisition by Amgen Inc (NASDAQ:AMGN) and has also chaired ImCheck Therapeutics and Repare Therapeutics through their respective acquisitions.
Founder John Flavin shifted to Lead Independent Director, according to the announcement, continuing to serve on the board after leading the company since its founding.
Wednesday’s MICVO Data Readout
Pyxis Oncology said it will host a live webcast Wednesday at 7:30 a.m. Eastern to present updated Phase 1 data on micvotabart pelidotin (MICVO), its lead antibody-drug conjugate. The trial evaluates MICVO as a monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who have received prior treatment, classified as second-line and beyond (2L+).
Alan L. Ho, M.D., of Memorial Sloan Kettering Cancer Center, will join company management to discuss safety, efficacy and next steps.
Trading Metrics, Technical Analysis
Pyxis Oncology has a market capitalization of approximately $324.46 million. Its stock has traded between a 52-week high of $5.55 and a 52-week low of $1.03.
PYXS has a Relative Strength Index (RSI) of 64.20.
Over the past 12 months, the small-cap biotech stock has gained 98.47%.
With strong Momentum in the 98th percentile, Benzinga’s Edge Stock Rankings indicate that Pyxis Oncology has a positive price trend across all time frames.
See More: Top Value Stocks
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Spyro the Dragon on Shutterstock.com
Login to comment